BioNTech (NASDAQ:BNTX) Stock Price Down 6.5% - Here's Why

Key Points

• BioNTech's stock price fell 6.5% on Monday, reaching a low of $103.80 before recovering slightly to close at $105.17, with trading volume down 38% from the average.
• Despite the recent drop, several analysts maintain a positive outlook, with an average price target of $135.80 and a consensus rating of "Moderate Buy."
• In its latest earnings report, BioNTech reported a revenue of $306.46 million, significantly exceeding estimates, but posted a loss of ($1.60) EPS that missed expectations by $0.19.

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report)'s stock price fell 6.5% during mid-day trading on Monday . The stock traded as low as $103.80 and last traded at $105.17. 576,851 shares traded hands during trading, a decline of 38% from the average session volume of 928,656 shares. The stock had previously closed at $112.46.

Analysts Set New Price Targets

Several brokerages recently issued reports on BNTX. Wall Street Zen raised BioNTech from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. Wells Fargo & Company set a $150.00 target price on BioNTech and gave the company an "overweight" rating in a research report on Tuesday, August 5th. HC Wainwright reaffirmed a "buy" rating and set a $136.00 target price on shares of BioNTech in a research report on Monday, September 8th. Bank of America boosted their price objective on BioNTech from $126.00 to $134.00 and gave the stock a "buy" rating in a research report on Tuesday, August 5th. Finally, Leerink Partners set a $112.00 price objective on BioNTech in a research report on Monday, June 2nd. Thirteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $135.80.

BioNTech Price Performance

The company has a current ratio of 8.61, a quick ratio of 8.48 and a debt-to-equity ratio of 0.01. The business has a 50-day moving average price of $108.79 and a 200 day moving average price of $103.98. The stock has a market cap of $23.26 billion, a PE ratio of -60.46 and a beta of 1.39.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported ($1.60) EPS for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The firm had revenue of $306.46 million for the quarter, compared to analysts' expectations of $161.26 million. During the same period in the prior year, the company earned ($3.36) EPS. The firm's quarterly revenue was up 102.6% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. As a group, research analysts forecast that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

Institutional Trading of BioNTech

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Banque Cantonale Vaudoise bought a new stake in shares of BioNTech during the 1st quarter valued at $36,000. LRI Investments LLC raised its stake in shares of BioNTech by 234.6% during the 2nd quarter. LRI Investments LLC now owns 445 shares of the company's stock valued at $47,000 after purchasing an additional 312 shares during the period. Tower Research Capital LLC TRC raised its stake in shares of BioNTech by 118.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company's stock valued at $60,000 after purchasing an additional 305 shares during the period. Hantz Financial Services Inc. raised its stake in shares of BioNTech by 472.0% during the 2nd quarter. Hantz Financial Services Inc. now owns 572 shares of the company's stock valued at $61,000 after purchasing an additional 472 shares during the period. Finally, Banque Transatlantique SA bought a new stake in shares of BioNTech during the 1st quarter valued at $80,000. 15.52% of the stock is currently owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.